Comparative Pharmacology
Head-to-head clinical analysis: DRAXIMAGE DTPA versus TECHNETIUM TC 99M MERTIATIDE KIT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DRAXIMAGE DTPA versus TECHNETIUM TC 99M MERTIATIDE KIT.
DRAXIMAGE DTPA vs TECHNETIUM TC 99M MERTIATIDE KIT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DRAXIMAGE DTPA (technetium Tc-99m pentetate) is a radiopharmaceutical that, after intravenous injection, distributes in the extracellular space and is cleared by glomerular filtration. It allows imaging of renal function and structure by emitting gamma radiation detectable by a gamma camera.
Technetium Tc 99m mertiatide is a radiopharmaceutical diagnostic agent that undergoes renal tubular secretion and glomerular filtration, allowing for dynamic imaging of renal function and urinary tract patency.
Diagnostic imaging: 3-5 mCi (111-185 MBq) IV for renal studies; 10-20 mCi (370-740 MBq) IV for lung perfusion imaging.
1-10 mCi (37-370 MBq) intravenously as a single dose for renal imaging.
None Documented
None Documented
Terminal elimination half-life is approximately 1.6 hours (range 1.2-2.0 hours) in patients with normal renal function; prolonged in renal impairment (up to 50 hours in severe cases).
Terminal elimination half-life: approximately 1.5–2 hours for the non-protein-bound fraction; allows rapid imaging within 30 minutes and clearance from blood pool.
Renal: 95% within 24 hours via glomerular filtration; biliary/fecal: <5%.
Renal: approximately 50% excreted unchanged in urine within 2 hours; 70% within 24 hours. Biliary/fecal: negligible.
Category C
Category C
Diagnostic Radiopharmaceutical
Diagnostic Radiopharmaceutical